Remedium Bio announces the publication of preclinical data demonstrating the performance of its adjustable dose gene therapy platform – Prometheus™
Posted:
Prometheus™ was specifically designed as a subcutaneously injected gene delivery system, utilizing the same route of administration as most current therapeutic biologics. Remedium is applying the Prometheus™ platform technology to the development of its lead candidate RMD1202, a single injection disease-modifying treatment for type 2 diabetes and obesity.
Healthcare innovation continues to evolve at an extraordinary pace — driven by advances in AI, digital health, virtual care, and new models of medical education.
At the centre of many of these conversations is Prof. Shafi Ahmed, our Chairman and…
Owkin and Sanofi are expanding their artificial intelligence collaboration through a multi-year agreement to co-develop AI-enabled biopharma agents for drug research and development.
Read more here.
Attendees
Sponsors and Exhibitors
Contact us